Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 281 matching trials from the live ClinicalTrials.gov search.
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Genotropin (Recombinant Human Growth Hormone)
Drug
Lead sponsor
Mitchell Horwitz, MD
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

NCT05364684
Conditions
NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
LUM-201
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Growth Hormone Deficiency
Interventions
growth hormone (Nutropin)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Results available

Study of Testosterone and rHGH in FSHD

NCT03123913
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Testosterone Enanthate, Somatropin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, New York
Conditions
HIV Infections
Interventions
Somatropin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 13 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more
Conditions
Cystic Fibrosis
Interventions
Oral Glucose tolerance test, Whole body protein turnover, IV glucose tolerance test, Indirect Calorimetry, Dual Energy X-ray Absorptiometry (DEXA), Growth Hormone Stimulation Test
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Short Bowel Syndrome
Interventions
recombinant human growth hormone, diet modification
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Turner's Syndrome
Interventions
growth hormone, oxandrolone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
10 Years to 14 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study of Outcome After Therapy for Acromegaly

NCT01809808
Conditions
Acromegaly
Interventions
Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging, Adipose Tissue Biopsy
Procedure · Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Short Stature Children Born Small for Gestational Age (SGA)
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more
Conditions
ISS, SGA
Interventions
Somatrogon, Genotropin
Drug
Lead sponsor
Rabin Medical Center
Other
Eligibility
3 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Centennial, Colorado • Jacksonville, Florida + 9 more
Conditions
Mild Cognitive Impairment
Interventions
Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Growth Hormone Deficiency
Interventions
Genotropin, somatrogon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Conditions
Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions
somatropin [rDNA origin] for injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

NCT00206375
Conditions
Hypothyroidism
Interventions
Growth hormone, Growth hormone treatment and puberty
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hypopituitarism
Interventions
Arimidex (Anastrozole), Placebo, Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 18 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Supplementation Trial on Arginine With Metabolic Profiling

NCT03409380
Conditions
Protein, Amino Acid, Arginine
Interventions
Arginine Drink, Plain Drink
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Acromegaly
Interventions
Somatuline Autogel (lanreotide acetate), Home administration
Drug · Behavioral
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida